Cary Street Partners Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Cary Street Partners Investment Advisory's VRTX Position: Q2 2026 in Review
Cary Street Partners Investment Advisory reduced its Vertex Pharmaceuticals (VRTX) stake by 2.3% in Q2 2026, selling an estimated $5.76K and leaving 555 shares worth $276K. The position accounts for 0.06% of the portfolio, ranked #313.
Cary Street Partners Investment Advisory first reported a position in VRTX in Q3 2020 and has held it in 17 quarters since. The position peaked at $11.4M in Q2 2024. 1,406 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Cary Street Partners Investment Advisory held 555 shares of Vertex Pharmaceuticals worth $276K as of Q2 2026.
- Cary Street Partners Investment Advisory sold 13 Vertex Pharmaceuticals shares in Q2 2026, an estimated $5.76K.
- Vertex Pharmaceuticals made up 0.06% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #313 holding.
- Cary Street Partners Investment Advisory first reported a position in Vertex Pharmaceuticals in Q3 2020 and has held it in 17 quarters since.
- Cary Street Partners Investment Advisory's Vertex Pharmaceuticals position peaked at $11.4M in Q2 2024.
- 1,406 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.